INFLUENZA EVOLUTION: Challenges for diagnosis

Similar documents
In the Name of God. Talat Mokhtari-Azad Director of National Influenza Center

Current Vaccines: Progress & Challenges. Influenza Vaccine what are the challenges?

Evolution of influenza

Reagents for the Typing of Human Influenza Isolates 2011

This product was developed by the Victorian Infectious Diseases Reference Laboratory (VIDRL) in its capacity as a WHO Collaborating Centre for

Update on influenza monitoring and vaccine development

Modeling the Antigenic Evolution of Influenza Viruses from Sequences

دکتر بهروز نقیلی استاد بیماریهای عفونی مرکس تحقیقات بیماریهای عفونی و گرمسیری پاییس 88

Patterns of hemagglutinin evolution and the epidemiology of influenza

REAGENTS FOR THE TYPING OF HUMAN INFLUENZA ISOLATES 2017

INFLUENZA-2 Avian Influenza

TITLE: Influenza A (H7N9) virus evolution: Which genetic mutations are antigenically important?

Incorporating virologic data into seasonal and pandemic influenza vaccines

Where Health Care Meets Policy. with Dr. Mike Magee

Human Influenza. Dr. Sina Soleimani. Human Viral Vaccine Quality Control 89/2/29. November 2, 2011 HVVQC ١

Lecture 19 Evolution and human health

Thursday, September 14, :00 AM ET. Overview. Creating Flu Vaccines: Strain Selection. Assessing Vaccine Effectiveness

Influenza: The Threat of a Pandemic

Vaccine. Design and Manufacturing. Liting Bi.

Nanoparticulate Vaccine Design: The VesiVax System

Correlates of Protection for Flu vaccines and Assays Overview. by Simona Piccirella, PhD Chief Executive Officer

Influenza or flu is a

Cover Page. The handle holds various files of this Leiden University dissertation

Early Diagnosis: A Critical Step in Bird Flu Prevention

What is influenza virus? 13,000 base RNA genome: 1/ the size of the human genome

NASDAQ:NVAX Novavax, Inc. All rights reserved.

Challenges in Vaccine Production and Rapid Scale up to Meet Emerging Pandemic Threats

Agricultural Outlook Forum Presented: February 16, 2006 THE CURRENT STATE OF SCIENCE ON AVIAN INFLUENZA

INFLUENZA VIRUS. INFLUENZA VIRUS CDC WEBSITE

ANALYZING AND MANAGING RISKS IN LIFE SCIENCES RESEARCH

Transforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago

The Flu: The Virus, The Vaccine, and Surveillance. Joanna Malukiewicz GK12 Program School of Life Sciences Arizona State University

Blocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model

Primary Isolation and Cultivation of Viruses

Influenza Virus: Evolution of a Deadly Virus in our World

Pandemic Influenza influenza epidemic: realization of a worst-case scenario

Acute respiratory illness This is a disease that typically affects the airways in the nose and throat (the upper respiratory tract).

Grade Level: Grades 9-12 Estimated Time Allotment Part 1: One 50- minute class period Part 2: One 50- minute class period

The A(H7N9) influenza outbreak in China

M I C R O B I O L O G Y

Study the Evolution of the Avian Influenza Virus

Overview of the Influenza Virus

Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC

Competing co-infections of LP and HP AIV H7N7

Introduction to Avian Influenza

100 years of Influenza Pandemic and the prospects for new influenza vaccines

MEETING THE STANDARDS: FDA MANDATORY RAPID INFLUENZA DETECTION TEST (RIDTs) RECLASSIFICATION

Influenza: The past, the present, the (future) pandemic

Application of Reverse Genetics to Influenza Vaccine Development

Overview of assays for influenza vaccines immunology evaluation

Influenza Global Epidemiologic Update

A secret about creationism

Detection of neuraminidase-inhibiting antibodies for measurement of Influenza vaccine immunogenicity

What is Influenza? Patricia Daly MD, FRCPC Medical Health Officer and Medical Director of Communicable Disease Control

Mapping the Antigenic and Genetic Evolution of Influenza Virus

Lab 2: Diagnostic Tests in Clinical Virology Laboratories 450 MIC PRACTICAL PART SECTION (30397) 2018 (450 MIC) AMAL ALGHAMDI - HUDA ALKHTEEB 1

Recommended laboratory tests to identify influenza A/H5 virus in specimens from patients with an influenza-like illness

ph1n1 H3N2: A Novel Influenza Virus Reassortment

Lesson 20 Study Guide: Medical Biotechnology Pandemic Flu & Emergent Disease

Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses

ORTHOMYXOVIRUSES INFLUENZA VIRUSES. (A,B and C)

2009 (Pandemic) H1N1 Influenza Virus

Questions and Answers

Influenza. By Allison Canestaro-Garcia. Disease Etiology:

Pandemic Influenza Preparedness

SCIENTIFIC DISCUSSION

Influenza B viruses are not divided into subtypes, but can be further broken down into different strains.

Weekly Influenza & Respiratory Illness Activity Report

Minnesota Influenza Geographic Spread

STUDIES UPON THE POSSIBILITIES OF AVIAN INFLUENZA VIRUSES CULTIVATION IN CHICK EMBRYOS AT DIFFERENT AGE

Laboratory Diagnosis of Viral Infections affect the Lower Respiratory Tract. M Parsania, Ph.D. Tehran Medical Branch, Islamic Azad University

Minnesota Influenza Geographic Spread

SEROLOGICAL DIAGNOSIS OF VIRAL INFECTIONS:

Influenza Testing Today: Keeping Up with a Moving Target

Running head: INFLUENZA VIRUS SEASON PREPAREDNESS AND RESPONSE 1

ECMO and the 2013 Influenza A H1N1 Epidemic

Influenza vaccines. Cheryl Cohen

Influenza Viruses A Review

Synthetic Genomics and Its Application to Viral Infectious Diseases. Timothy Stockwell (JCVI) David Wentworth (JCVI)

INFLUENZA A VIRUS. Structure of the influenza A virus particle.

Chinese Influenza Weekly Report

OIE Situation Report for Avian Influenza

Nothing to disclose. Influenza Update. Influenza Biology. Influenza Biology. Influenza A 12/15/2014

Laboratory Diagnosis of Avian Influenza and Newcastle Disease

Kyoung-Jin Yoon 1, Bruce H. Janke, Rick W. Swalla, Gene Erickson

Weekly Influenza & Respiratory Illness Activity Report

NOTES CONTAMINATION OF CYNOMOLGUS MONKEY KIDNEY CELL CULTURES BY HEMAGGLUTINATING SIMIAN VIRUS (SV 5)

Influenza Infection In Human. Dr. Zuhaida A. Jalil Surveillance Sector Disease Control Division, MOH Malaysia 3 May 2018

Patricia Fitzgerald-Bocarsly

Cristina Cassetti, Ph.D.

Preparing for the Fall Flu Season. Jonathan Gubbay Medical Microbiologist Public Health Laboratory OAHPP

Overview and Future Plans: Laboratory Working Group. John Wood and Othmar Engelhardt CONSISE Open Meeting, Cape Town South Africa 4 September 2013

Influenza. Gwen Clutario, Terry Chhour, Karen Lee

Development of a Novel Recombinant Influenza Vaccine in Insect Cells

Vaccinology 101 for Fellows

Report on virological surveillance of influenza activity in the Romania 2014/15 season

Pandemic Influenza and Vaccine Preparedness. GIP - Global Influenza Programme WHO2017

Avian influenza Avian influenza ("bird flu") and the significance of its transmission to humans

Transcription:

INFLUENZA EVOLUTION: Challenges for diagnosis Jairo A. Méndez-Rico Influenza Team PAHO/WHO, Washington, DC

Overview Every year, influenza infects up to one in five people around the world, and causes up to half a million deaths Human immune system can detect and destroy the virus However, people can catch flu many times throughout their lifetimes

Viral evolution Evolutionary process lead changes generating new viruses, therefore a new infection and a new immune response has to be established Evolution is a natural process that can occur spontaneously However, viruses are pressured to change: Immune response, vaccines, new cell receptors

Viral evolution Genetic punctual mutation aa change Not aa change Same protein Altered protein Deleterious Beneficial

Viral evolution: antigenic drift Genetic punctual mutation aa change Not aa change Same antigen New antigen Well recognized Not recognized

Viral evolution: antigenic drift Genetic punctual mutation aa change Not aa change Same antigen New antigen Antigenic drift Well recognized Not recognized

Viral evolution: influenza Before 2009 A/H1N1 A/H3N2 B/Vic B/Yam Different viruses with different proteins: Same viruses, same proteins, different lineages Hemagglutinin 1 / 3 Neuraminidase 1 / 2 Hemagglutinin Neuraminidase

Viral evolution: influenza Mutations to the HA1 region of the hemagglutinin protein are thought to drive the majority of antigenic drift in the influenza virus How does it affect lab diagnosis? James Stevens and Ian A. Wilson. SSRL Science Highlight - August 2004

Viral evolution: impact for characterization Lab characterization of antigenic phenotype is possible through the hemagglutination assays, based on: Hemagglutination Hemagglutination inhibition

Haemagglutination Science 4 July 1941: Vol. 94 no. 2427 pp. 22-23 it was noted that the red cells of the infected chick agglutinated in the alantoic fluid.

Haemagglutination + = Non agglutinated RBC Influenza virus Haemagglutination Depends of viral HA to bind polysaccharides of RBS membrane

Haemagglutination inhibition J Exp Med 1 January 1942: Vol. 75 pp. 49-64 it was shown that the addition of specific immune serum inhibited the agglutination in the presence of the homologous virus

Haemagglutination inhibition + + Influenza virus Specific antibodies = Y Y Y Y Depends of specific antibodies to bind (opsonize) viral HA Haemagglutination inhibition

The challenge Y Y Y Y Haemagglutination Haemagglutination inhibition Since both process depend on HA, antigenic drift may alter the performance of the assays

The challenges Since the 1990s the receptor-binding characteristics of A(H3N2)have evolved

Faster evolution Bedford et al. elife 2014;3:e01914. DOI: 10.7554/eLife.01914

The challenges Since the 1990s the receptor-binding characteristics of A(H3N2)have evolved Two major consequences: 1. Difficulty for isolation in eggs 2. Progressive reduction in the ability to bind and agglutinate chicken RBC (1990s) and turkey RBC (2000s)

The challenge 1. Difficulty for isolation in eggs -Low egg isolation rates (Limited availability of candidate vaccine viruses) -Selective pressures (egg adaptation mutations)

Categorization in 2 groups: 1. Restriction to sialoglycans 2. Restriction to egg glycans Less prone to undergoing receptor (antigenic) drift

Egg-adapted strain was antigenically distinct from WHO recommended vaccine prototipe

The challenge: reducing the impact on vaccine selection Impact on vaccine selection

The solutions Change the age at which embryonated eggs are inoculated (9-10 days to 13-15 days old) Change the inoculation route (to allantoic cavity) Change the egg incubation T o (from 33 o C to 35 o C) Low egg isolation rates Improved up to 18%

The solutions Utilizing egg/cell paired viruses (routine characterization) Egg adaptation mutations To estimate how differences between the two may alter HI profiles; helps to select the best A(H3N2) candidate vaccine viruses

The challenge 2. Progressive reduction in the ability to bind and agglutinate chicken RBC (1990s) and turkey RBC (2000s) - H3N2 Inadequate sialic acid receptor interactions -Technical difficulties to perform serologic assays (IH)

Decrease in HIA sensitivity Bedford et al. elife 2014;3:e01914. DOI: 10.7554/eLife.01914 Adapted from: Rambaut A. Integrating influenza antigenic dynamics with molecular evolution. Geneva, 2014

The challenge: Improving HI assays Additional limitations: Time consuming Hard to standardize Inter- and Intra-laboratory variability RBCs from different species are used (turkey, guinea pig, human, chicken, horse, goose) RBC lots can be variable Results can be affected by antibody source Interpretation is subjective Low sensitivity to detect antibodies against avian viruses (Stevens J. CDC. Geneva, 2014)

The solutions Alternatives proposed to improve: -Sensitivity -Accuracy -Sample throughput -Reproducibility between labs Bead formats Solid matrices

-Bead formats (surrogate RBC) Purified Synthetic

-Bead formats (surrogate RBC) Very promising results Reproducible Size of the bead is critical Bead stability is variable Beads are affected by buffer Glycan choice

-Solid matrices Glycan coated bead or RBC vesicle Solid phase + synthetic glycans Solid phase + specific Abs Solid phase + viral HA

The solutions Virus or recombinant protein Synthetic sialyl-glycans RBC membrane vesicles RBC membrane fragments Purified proteins with unspecified glycan composition Detection options Fluorescence Chemiluminescence FRET Direct binding

Conclusions Evolution lead changes generating new influenza viruses Mutations of HA protein generate antigenic drift (specially AH3N2) These changes affect the performance of characterization tests Mutations (drift) may be introduced as part of egg-based vaccine production

Conclusions New methods (or improved) have to be designed to assess serologic characterization of A(H3N2) (synthetic carbohydrates, surrogate RBC ) There are several options (ongoing) to improve HA/HAI assays but also several challenges! Keep it simple Sensitivity/reliability/reproducibility Applicable to all subtypes Keeping costs down

Conclusions More studies have to be developed sharing viruses increase the chances of better approaches

GRACIAS!